Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

Contributed by: PR Newswire

Tags

Bioartic-Awards

More Like This

Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Long-term treatment data for lecanemab to be presented at AAIC 2024

BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease

Lecanemab winner in two categories at The Scrip Awards 2023

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD